Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer

Phase 2

Completed

• Conditions: Breast Cancer; Hormone Receptor Positive Tumor; Metastatic Breast Cancer
• Interventions: Drug: Pegylated liposomal doxorubicin; Drug: Ipilimumab; Drug: Cyclophosphamide; Drug: Nivolumab

• Registration Number: NCT03409198
• Lead Sponsor: Oslo University Hospital

Brief Summary

Breast cancer is rarely curable after metastasis, and the therapeutic options are limited. Interestingly, the host immune response is strongly predictive for the effect of chemotherapy in subgroups of patients with breast cancer. The aim is to release the brake on the immune response by use of ipilimumab, which blocks CTLA-4 and may deplete regulatory T cells, combined with nivolumab (anti PD1). Importantly, it is possible that non-responders to nivolumab/ipilimumab (nivo/ipi) can be turned responders by use of immunogenic chemotherapy.

Detailed Description

There is compelling evidence from animal studies, supported by data from humans, that some chemotherapeutic agents are immunogenic. Doxorubicin and cyclophosphamide have been shown to be particularly powerful inducers of immunogenic cell death. Both agents fulfil 5/5 criteria established for assessing the immunogenicity of different chemotherapeutic drugs. There is also strong evidence from humans, particularly in breast cancer, indicating that the clinical effect of doxorubicin and cyclophosphamide depends on the host immune response. Further, these agents have been shown to induce a Type I interferon immune response in breast cancer. Taken together, there is a strong rationale for synergy between doxorubicin/cyclophosphamide and PD-1/CTLA-4 blockade. The trial combines nivolumab and ipilimumab with established 1st choice chemotherapy in patients with metastatic hormone reseptor positive breast cancer. Nivolumab/ipilimumab (nivo/ipi) may i) potentiate the patient´s spontaneous anti-tumor immune response ii) synergize with chemotherapeutic agents that induce immunological cell death

Study Timeline

• Study First Submitted: 2017-12-04
• Study First Submitted QC: 2018-01-18
• Study Start: 2018-01-21
• Study First Posted: 2018-01-24
• Primary Completion: 2022-05-11
• Study Completion: 2022-05-11
• Status Verified: 2024-02
• Last Update Submitted: 2024-10-09
• Last Update Posted: 2024-10-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

1. Metastatic hormone receptor positive breast cancer (primary or recurrent), defined as ER+ >1% in metastatic biopsy (archival material or study biopsy) or cytology and HER2 negative in the last biopsy or cytology evaluable for HER2. HER2-analysis is to be perfomed according to national criteria.
2. Adequate core or excisional study biopsy of a tumor lesion. Lesions in previously irradiated areas may only be used for the biopsy if the lesion has appared or progressed after radiation. No anti-tumor treatment is allowed between the time point for biopsy and study entry.
3. Measurable metastatic disease according to RECIST
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
5. Signed Informed Consent Form
6. Women or men aged ≥ 18 years
7. A minimum of 12 months from adjuvant/neoadjuvant chemotherapy with antracyclins to relapse disease
8. A maximum of one previous line with chemotherapy in the metastatic setting
9. Chemotherapy is considered as preferred treatment
10. Previous endocrine and targeted therapy is allowed
11. No use of systemic corticosteroids at study entry
12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
13. Female subjects of childbearing potential should agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year, during the treatment period and for at least 5 months after the last dose of study therapy.
14. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy
15. Able to swallow and retain orally administered medication
16. Adequate organ function as defined in Table 1

Exclusion Criteria

1. Malignancies other than breast cancer within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)

2. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 8 weeks prior to randomization

3. Known CNS disease, except for asymptomatic CNS metastases, provided all of the following criteria are met:

   1. Measurable disease outside the CNS
   2. Asymptomatic for CNS disease > 4 weeks
   3. No ongoing requirement for corticosteroids as therapy for CNS disease
   4. No radiation of brain lesions within 2 weeks prior to randomization
   5. No leptomeningeal disease

4. Uncontrolled pleural effusion, pericardial effusion, or ascites. Patients with indwelling catheters (e.g., PleurX®) are allowed

5. Uncontrolled tumor-related pain. Patients requiring narcotic pain medication must be on a stable regimen at study entry. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to randomization

6. Ionized calcium > 1.2 x UNL. The use of bisphosphonates is allowed

7. Pregnant or breastfeeding

8. Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)

9. Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina Patients with a known left ventricular ejection fraction (LVEF) < 40% will be excluded. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF < 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate

10. Severe infection within 21 days prior to randomization, requiring hospitalization

11. Received oral or IV antibiotics within 1 week prior to Cycle 1, Day 1. Patients receiving routine antibiotic prophylaxis (e.g., to prevent chronic obstructive pulmonary disease exacerbation or for dental extraction) are eligible

12. Major surgical procedure within 21 days prior to randomization or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis. Placement of central venous access catheter(s) is not considered a major surgical procedure and is therefore permitted

13. A history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

14. Known hypersensitivity to any of the components of the investigational products

15. A history of autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxin, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., no psoriatic arthritis) are permitted provided that they meet all of the following conditions:

    1. Rash must cover less than 10% of body surface area.
    2. Disease is well controlled at baseline and only requiring low potency topical steroids
    3. No acute exacerbations of underlying condition within the last 12 months (not requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, high potency or oral steroids)

16. Undergone allogeneic stem cell or solid organ transplantation

17. A history of idiopathic pulmonary fibrosis pneumonitis, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted

18. A positive test for HIV

19. Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C. Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA

20. Active tuberculosis

21. Currently receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment

22. Received treatment with immune checkpoint modulators, including anti-CTLA-4, anti-PD-1, or anti-PD-L1 therapeutic antibodies

23. Received treatment with systemic immunostimulatory agents (including but not limited to interferons or IL-2) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization

24. Received treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial

    1. Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study
    2. Patients with a history of allergic reaction to IV contrast requiring steroid pre-treatment should have baseline and subsequent tumor assessments performed using MRI
    3. The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed

25. Received anti-cancer therapy (medical agents or radiation) within 2 weeks prior to study Cycle 1, Day 1. Palliative radiotherapy for bone lesions is allowed up to 7 days before start of therapy.

26. A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator

27. Known psychiatric or substance abuse disorders that would interfere with cooperation and the requirements of the trial

28. Received a live vaccine within 30 days of planned start of study therapy, or is expected to receive such a vaccine while on therapy

    a. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

29. Any reason why, in the opinion of the investigator, the patient should not participate

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A	Pegylated liposomal doxorubicin	Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
Arm A	Cyclophosphamide	Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
Arm B	Ipilimumab	Chemo + ipilimumab + nivolumab
Arm B	Pegylated liposomal doxorubicin	Chemo + ipilimumab + nivolumab
Arm B	Cyclophosphamide	Chemo + ipilimumab + nivolumab
Arm B	Nivolumab	Chemo + ipilimumab + nivolumab

Primary Outcome Measures

Name	Time	Method
Toxicity: CTCAE v4.0	3 years	Assessment of toxicity of combined treatment with ipilimumab, nivolumab, pegylated liposomal doxorubicin and cyclophosphamide (ipi/nivo/chemo)
Progression-free survival (PFS)	We expect to reach the data-driven time point for PFS-analysis (95% PFS in the control group) approximately 3 years after the study opens. If this is not met within 24 months after inclusion of the last patient, the PFS-analysis will be performed at this	Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: Progression-free survival (PFS); compare the PFS rates when 95% of patients in the control croup have PD

Secondary Outcome Measures

Name	Time	Method
Duration of Response (DR)	3 years	Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: duration of response (DR)
Overall Survival (OS)	5 years	Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: overall survival (OS)
Duration of Response (DR) in cross-over arm	3 years	Assessment of clinical response in ipi/nivo group: duration of response (DR)
Overall Suvival (OS) in cross-over arm	5 years	Assessment of clinical response in ipi/nivo group: overall survival (OS)
Toxicity, cross-over arm, CTCAE v4.0	3 years	Assessment of toxicity of ipi/nivo (without chemotherapy) in cross-over arm
Objective tumor Response Rate (ORR)	3 years	Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: Objective tumor response rate (ORR)
Durable tumor Response Rate (DRR)	3 years	Assessment of clinical response in ipi/nivo/chemo group compared to chemo only group: durable tumor response rate (DRR; \>6 months)
Objective tumor Response Rate (ORR) in cross-over arm	3 years	Assessment of clinical response in ipi/nivo group: Objective tumor response rate (ORR)
Durable tumor Response Rate (DRR) in cross-over arm	3 years	Assessment of clinical response in ipi/nivo group: durable tumor response rate (DRR; \>6 months)
Clinical Benefit Rate (CBR)	3 years	Proportion of patients with an objective tumor response or with stable disease lasting at least 6 months
Clinical Benefit Rate (CBR) in cross-over arm	3 years	Proportion of patients with an objective tumor response or with stable disease lasting at least 6 months
PD-L1 expression	3 years	Assessment of PD-L1 expression, mutation load and immune gene expression as biomarkers for clinical response
Chalder Fatigue Questionnaire (FQ)	3 years	Assessment of patient reported outcomes, as measured by the Chalder Fatigue Questionnaire (FQ)
Pain intensity	3 years	Assessment of patient reported outcomes, as measured by an 11 point Numerical Rating Scale (NRS) for pain intensity
EORTC QLQ-C15-PAL	3 years	Assessment of patient reported outcomes, as measured by the EORTC QLQ-C15-PAL
Biological response in molecular subtypes of breast cancer	3 years	Comparison of clinical and biological response in molecular subtypes of breast cancer

Trial Locations

Locations (6)

Oslo University Hospital; 🇳🇴 Oslo, Norway

Stavanger University Hospital; 🇳🇴 Stavanger, Norway

Soerlandet Hospital HF Kristiansand; 🇳🇴 Kristiansand, Norway

Institut Jules Bordet; 🇧🇪 Brussels, Belgium

Cliniques universitaires Saint-Luc; 🇧🇪 Bruxelles, Belgium

CHU UCL Namur; 🇧🇪 Namur, Belgium